NEWS & PUBLICATIONS LATEST NEWS NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025April 25, 2025 Press Releases Publications NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025April 25, 2025 NextPoint Therapeutics to Highlight Antibody-Drug Conjugate (ADC) and T Cell Engager (TCE) Preclinical Findings Targeting Novel B7-H7 Pathway at AACR Annual MeetingApril 7, 2025 NextPoint Therapeutics to Showcase Multimodal Oncology Pipeline Targeting B7-H7-Positive Patients at the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 NextPoint Therapeutics to Participate in the Stifel Healthcare ConferenceNovember 13, 2024 NextPoint Therapeutics Announces Upcoming Poster Presentation on a B7-H7 Directed T Cell Engager Therapy at SITC2024November 7, 2024 NextPoint Therapeutics to Participate in the Leerink Partners Biopharma Private Company ConnectOctober 9, 2024 NextPoint Therapeutics Announces First-in-class T Cell Engager NPX372 As New Drug Candidate Targeting B7-H7 in Solid TumorsSeptember 5, 2024 NextPoint Therapeutics Chief Executive Officer Ivan Cheung Named to the 2024 TIME100 Health ListMay 6, 2024 NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid TumorsFebruary 20, 2024 NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital ManagementFebruary 14, 2024 NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital ManagementFebruary 14, 2024 NextPoint Therapeutics Appoints Ivan Cheung as Chief Executive OfficerFebruary 1, 2024 NextPoint Therapeutics Appoints Tatiana Novobrantseva, PhD, as Chief Scientific OfficerJanuary 16, 2024 NextPoint Therapeutics Announces IND Clearance from the FDA to Advance NPX887, a Novel Therapeutic Targeting HHLA2 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid TumorsDecember 7, 2023 NextPoint Therapeutics Announces First Patient Dosed in Phase 1a/b Clinical Trial of NPX267, a Novel Therapeutic Targeting KIR3DL3 to Reactivate Exhausted T and NK Cells in HHLA2+ Solid TumorsAugust 17, 2023 Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of DirectorsMarch 21, 2023 NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical OfficerFebruary 21, 2023 NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology ProgramsJanuary 10, 2023 NextPoint Therapeutics to Showcase Pioneering Preclinical Data on NPX125, a Novel B7-H7 Targeted Antibody-Drug Conjugate (ADC) at AACR Annual Meeting 2025April 25, 2025 NextPoint Therapeutics Presents Poster at 21st Annual Meeting of the Association of Cancer Immunotherapy (CIMT) in Mainz, GermanyMay 15, 2024 Gordon J. Freeman, PhD, FAACR, Recognized with 2024 AACR-Cancer Research Institute Lloyd J. Old Award in Cancer ImmunologyFebruary 21, 2024 NextPoint Therapeutics Presents Poster on Precision Immuno-oncology at Seventh International Cancer Immunotherapy Conference in Milan, ItalyNovember 10, 2023 BioTech 2050 Podcast Episode 160: BIO Special: New vision for immunotherapy, Detlev Biniszkiewicz, Founder & CEO, NextPoint TxJune 7, 2023 NextPoint Therapeutics Presents Poster on NPX267 at 37th SITC Annual Meeting in Boston, MANovember 8, 2022
